Astrazeneca (AZN) Total Debt (2009 - 2026)
Astrazeneca (AZN) posted quarterly Total Debt of $29.5 billion for Q2 2026, down 5.5% year-over-year from $31.2 billion in Q2 2025, and up 158.52% quarter-over-quarter from -$50.4 billion in Q1 2026.
Astrazeneca (AZN) Total Debt (2009 - 2026) Analysis & Trends
Astrazeneca's Total Debt history runs 18 years deep, the most recent figure standing at $29.5 billion for Q2 2026.
- In Q2 2026, Total Debt fell 5.5% year-over-year to $29.5 billion; the TTM figure through Jun 2026 stood at $29.5 billion (down 5.5% YoY), while the FY2025 annual figure was $27.8 billion, down 3.55% from the prior year.
- Total Debt for Q2 2026 stood at $29.5 billion, up from -$50.4 billion in the prior quarter.
- The five-year high for Total Debt was $31.2 billion in Q2 2025, with the low at -$55.2 billion in Q3 2024.
- The 5-year median for Total Debt is -$47.6 billion (2022), against an average of -$19.1 billion.
- The sharpest annual moves came in 2022 and 2025: Total Debt tumbled 127.78% in 2022, then gained 11.89% in 2025.
- Astrazeneca's Total Debt stood at $28.3 billion in 2022, then declined by 2.78% to $27.5 billion in 2023, then climbed by 4.91% to $28.8 billion in 2024, then decreased by 3.55% to $27.8 billion in 2025, then rose by 6.01% to $29.5 billion in 2026.
- Business Quant data shows AZN's Total Debt at $29.5 billion in Q2 2026, -$50.4 billion in Q1 2026, and $27.8 billion in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 645.88 Bn | 625.12 Bn | 17.26 Bn | 49.04 Bn |
| 2 | AbbVie | 463.46 Bn | 456.89 Bn | 12.70 Bn | 70.82 Bn |
| 3 | Merck | 367.92 Bn | 360.78 Bn | 12.21 Bn | 53.91 Bn |
| 4 | Novartis Ag | 297.71 Bn | 290.02 Bn | 11.24 Bn | 9.59 Bn |
| 5 | Astrazeneca | 255.55 Bn | 250.65 Bn | 12.86 Bn | 29.49 Bn |
| 6 | Amgen | 234.52 Bn | 220.53 Bn | 7.24 Bn | 62.75 Bn |
| 7 | Gilead Sciences | 178.22 Bn | 175.04 Bn | 6.22 Bn | 28.66 Bn |
| 8 | Pfizer | 158.57 Bn | 146.88 Bn | 10.94 Bn | 63.19 Bn |
| 9 | Gsk | 105.32 Bn | 101.15 Bn | 8.24 Bn | -25.96 Bn |
| 10 | Sanofi | 54.20 Bn | 46.82 Bn | 10.79 Bn | 25.19 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 29.49 Bn |
| Mar 31, 2026 | -50.40 Bn |
| Dec 31, 2025 | 27.82 Bn |
| Sep 30, 2025 | -48.67 Bn |
| Jun 30, 2025 | 31.21 Bn |
| Mar 31, 2025 | -52.76 Bn |
| Dec 31, 2024 | 28.84 Bn |
| Sep 30, 2024 | -55.24 Bn |
| Mar 31, 2024 | -53.71 Bn |
| Dec 31, 2023 | 27.49 Bn |
| Sep 30, 2023 | -45.60 Bn |
| Mar 31, 2023 | -51.98 Bn |
| Dec 31, 2022 | 28.28 Bn |
| Sep 30, 2022 | -47.56 Bn |
| Mar 31, 2022 | -53.30 Bn |
| Dec 31, 2021 | 29.79 Bn |
| Sep 30, 2021 | -52.88 Bn |
| Mar 31, 2021 | -23.40 Bn |
| Dec 31, 2020 | -22.72 Bn |
| Sep 30, 2020 | -32.03 Bn |